Cargando…
Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study
Introduction: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have recently been proposed as promising biomarkers in different immune-mediated disorders. We evaluated the plasma levels of MMP-9 and MMP-2 and their tissue inhibitors TIMP-1 and TIMP-2 in a patients...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688860/ https://www.ncbi.nlm.nih.gov/pubmed/36358365 http://dx.doi.org/10.3390/brainsci12111439 |
_version_ | 1784836376257101824 |
---|---|
author | Di Stefano, Vincenzo Tubiolo, Chiara Gagliardo, Andrea Presti, Rosalia Lo Montana, Maria Todisco, Massimiliano Lupica, Antonino Caimi, Gregorio Tassorelli, Cristina Fierro, Brigida Brighina, Filippo Cosentino, Giuseppe |
author_facet | Di Stefano, Vincenzo Tubiolo, Chiara Gagliardo, Andrea Presti, Rosalia Lo Montana, Maria Todisco, Massimiliano Lupica, Antonino Caimi, Gregorio Tassorelli, Cristina Fierro, Brigida Brighina, Filippo Cosentino, Giuseppe |
author_sort | Di Stefano, Vincenzo |
collection | PubMed |
description | Introduction: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have recently been proposed as promising biomarkers in different immune-mediated disorders. We evaluated the plasma levels of MMP-9 and MMP-2 and their tissue inhibitors TIMP-1 and TIMP-2 in a patients’ cohort with generalized myasthenia gravis (MG). Methods: Plasma concentrations of MMP-9, MMP-2, TIMP-1 and TIMP-2 were evaluated in 14 patients with generalized MG and 13 age- and sex-matched healthy controls. The severity of disease was assessed by the modified Osserman classification. Results: Compared to the healthy subjects, MG patients had increased plasma concentrations of MMP-9, but reduced plasma levels of MMP-2 and TIMP-1. MG patients also showed a positive correlation between MMP-2 concentrations and disease severity. An increase in MMP-9 levels and MMP-9/TIMP-1 ratio and a decrease in MMP-2 levels and MMP-2/TIMP-2 ratio were detected in patients with generalized MG. Higher levels of MMP-2 correlated with greater disease severity. Discussion: Our preliminary findings suggest that MMPs and TIMPs could play a role in the pathogenesis of MG and might be associated with the risk of clinical deterioration. |
format | Online Article Text |
id | pubmed-9688860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96888602022-11-25 Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study Di Stefano, Vincenzo Tubiolo, Chiara Gagliardo, Andrea Presti, Rosalia Lo Montana, Maria Todisco, Massimiliano Lupica, Antonino Caimi, Gregorio Tassorelli, Cristina Fierro, Brigida Brighina, Filippo Cosentino, Giuseppe Brain Sci Article Introduction: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have recently been proposed as promising biomarkers in different immune-mediated disorders. We evaluated the plasma levels of MMP-9 and MMP-2 and their tissue inhibitors TIMP-1 and TIMP-2 in a patients’ cohort with generalized myasthenia gravis (MG). Methods: Plasma concentrations of MMP-9, MMP-2, TIMP-1 and TIMP-2 were evaluated in 14 patients with generalized MG and 13 age- and sex-matched healthy controls. The severity of disease was assessed by the modified Osserman classification. Results: Compared to the healthy subjects, MG patients had increased plasma concentrations of MMP-9, but reduced plasma levels of MMP-2 and TIMP-1. MG patients also showed a positive correlation between MMP-2 concentrations and disease severity. An increase in MMP-9 levels and MMP-9/TIMP-1 ratio and a decrease in MMP-2 levels and MMP-2/TIMP-2 ratio were detected in patients with generalized MG. Higher levels of MMP-2 correlated with greater disease severity. Discussion: Our preliminary findings suggest that MMPs and TIMPs could play a role in the pathogenesis of MG and might be associated with the risk of clinical deterioration. MDPI 2022-10-26 /pmc/articles/PMC9688860/ /pubmed/36358365 http://dx.doi.org/10.3390/brainsci12111439 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Di Stefano, Vincenzo Tubiolo, Chiara Gagliardo, Andrea Presti, Rosalia Lo Montana, Maria Todisco, Massimiliano Lupica, Antonino Caimi, Gregorio Tassorelli, Cristina Fierro, Brigida Brighina, Filippo Cosentino, Giuseppe Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study |
title | Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study |
title_full | Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study |
title_fullStr | Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study |
title_full_unstemmed | Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study |
title_short | Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study |
title_sort | metalloproteinases and tissue inhibitors in generalized myasthenia gravis. a preliminary study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688860/ https://www.ncbi.nlm.nih.gov/pubmed/36358365 http://dx.doi.org/10.3390/brainsci12111439 |
work_keys_str_mv | AT distefanovincenzo metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy AT tubiolochiara metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy AT gagliardoandrea metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy AT prestirosalialo metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy AT montanamaria metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy AT todiscomassimiliano metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy AT lupicaantonino metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy AT caimigregorio metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy AT tassorellicristina metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy AT fierrobrigida metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy AT brighinafilippo metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy AT cosentinogiuseppe metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy |